Bisht Savita, Feldmann Georg, Soni Sheetal, Ravi Rajani, Karikar Collins, Maitra Amarnath, Maitra Anirban
The Sol Goldman Pancreatic Cancer Research Center, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
J Nanobiotechnology. 2007 Apr 17;5:3. doi: 10.1186/1477-3155-5-3.
Curcumin, a yellow polyphenol extracted from the rhizome of turmeric (Curcuma longa), has potent anti-cancer properties as demonstrated in a plethora of human cancer cell line and animal carcinogenesis models. Nevertheless, widespread clinical application of this relatively efficacious agent in cancer and other diseases has been limited due to poor aqueous solubility, and consequently, minimal systemic bioavailability. Nanoparticle-based drug delivery approaches have the potential for rendering hydrophobic agents like curcumin dispersible in aqueous media, thus circumventing the pitfalls of poor solubility.
We have synthesized polymeric nanoparticle encapsulated formulation of curcumin - nanocurcumin - utilizing the micellar aggregates of cross-linked and random copolymers of N-isopropylacrylamide (NIPAAM), with N-vinyl-2-pyrrolidone (VP) and poly(ethyleneglycol)monoacrylate (PEG-A). Physico-chemical characterization of the polymeric nanoparticles by dynamic laser light scattering and transmission electron microscopy confirms a narrow size distribution in the 50 nm range. Nanocurcumin, unlike free curcumin, is readily dispersed in aqueous media. Nanocurcumin demonstrates comparable in vitro therapeutic efficacy to free curcumin against a panel of human pancreatic cancer cell lines, as assessed by cell viability and clonogenicity assays in soft agar. Further, nanocurcumin's mechanisms of action on pancreatic cancer cells mirror that of free curcumin, including induction of cellular apoptosis, blockade of nuclear factor kappa B (NFkappaB) activation, and downregulation of steady state levels of multiple pro-inflammatory cytokines (IL-6, IL-8, and TNFalpha).
Nanocurcumin provides an opportunity to expand the clinical repertoire of this efficacious agent by enabling ready aqueous dispersion. Future studies utilizing nanocurcumin are warranted in pre-clinical in vivo models of cancer and other diseases that might benefit from the effects of curcumin.
姜黄素是从姜黄(姜黄属植物)根茎中提取的一种黄色多酚,在众多人类癌细胞系和动物致癌模型中已证明具有强大的抗癌特性。然而,由于其水溶性差,这种相对有效的药物在癌症和其他疾病中的广泛临床应用受到限制,因此全身生物利用度极低。基于纳米颗粒的药物递送方法有可能使姜黄素等疏水性药物分散于水性介质中,从而避免溶解性差的问题。
我们利用N - 异丙基丙烯酰胺(NIPAAM)与N - 乙烯基 - 2 - 吡咯烷酮(VP)和聚乙二醇单丙烯酸酯(PEG - A)的交联和无规共聚物的胶束聚集体,合成了包裹姜黄素的聚合物纳米颗粒制剂——纳米姜黄素。通过动态激光散射和透射电子显微镜对聚合物纳米颗粒进行的物理化学表征证实其粒径分布在50纳米范围内且较窄。与游离姜黄素不同,纳米姜黄素易于分散在水性介质中。通过软琼脂中的细胞活力和克隆形成试验评估,纳米姜黄素对一组人类胰腺癌细胞系的体外治疗效果与游离姜黄素相当。此外,纳米姜黄素对胰腺癌细胞的作用机制与游离姜黄素相似,包括诱导细胞凋亡、阻断核因子κB(NFκB)激活以及下调多种促炎细胞因子(IL - 6、IL - 8和TNFα)的稳态水平。
纳米姜黄素通过实现易于在水中分散,为扩大这种有效药物的临床应用范围提供了机会。未来有必要在癌症和其他可能受益于姜黄素作用的疾病的临床前体内模型中开展利用纳米姜黄素的研究。